Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge. We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.
LÄS MER
